Page 79 - Read Online

Page 22 of 25 Lue et al. J Cancer Metastasis Treat 2022;8:11 https://dx.doi.org/10.20517/2394-4722.2021.193

81. Fontan L, Hatcher J, Scott D, et al. Chemically induced degradation of malt1 to treat B-cell lymphomas. Blood 2019;134:2073. DOI
82. Hatcher JM, Du G, Fontán L, et al. Peptide-based covalent inhibitors of MALT1 paracaspase. Bioorg Med Chem Lett 2019;29:1336-
9. DOI PubMed
83. Quancard J, Klein T, Fung SY, et al. An allosteric MALT1 inhibitor is a molecular corrector rescuing function in an immunodeficient
patient. Nat Chem Biol 2019;15:304-13. DOI
84. Lu T, Connolly PJ, Philippar U, et al. Discovery and optimization of a series of small-molecule allosteric inhibitors of MALT1
protease. Bioorg Med Chem Lett 2019;29:126743. DOI PubMed
85. Fontán L, Qiao Q, Hatcher JM, et al. Specific covalent inhibition of MALT1 paracaspase suppresses B cell lymphoma growth. J Clin
Invest 2018;128:4397-412. DOI PubMed PMC
86. first-in-class MALT1 blocker deal. Nat Biotechnol 2019;37:112. DOI PubMed
87. Xia M, David L, Teater M, et al. BCL10 gain-of-function mutations aberrantly induce canonical and non-canonical NF-Kb activation
and resistance to IBRUTINIB in ABC-DLBCL. Blood 2020;136:2-3. DOI
88. Philippar U, Lu T, Vloemans N, et al. Abstract 5690: discovery of JNJ-67856633: a novel, first-in-class MALT1 protease inhibitor
for the treatment of B cell lymphomas. Cancer research 2020;80:5690. DOI
89. Kiyasu J, Miyoshi H, Hirata A, et al. Expression of programmed cell death ligand 1 is associated with poor overall survival in patients
with diffuse large B-cell lymphoma. Blood 2015;126:2193-201. DOI PubMed PMC
90. Godfrey J, Tumuluru S, Bao R, et al. DOI PubMed PMC
91. Ansell SM, Minnema MC, Johnson P, et al. Nivolumab for relapsed/refractory diffuse large B-Cell lymphoma in patients ineligible
for or having failed autologous transplantation: a single-arm, phase II study. J Clin Oncol 2019;37:481-9. DOI PubMed PMC
92. Smith SD, Till BG, Shadman MS, et al. Pembrolizumab with R-CHOP in previously untreated diffuse large B-cell lymphoma:
potential for biomarker driven therapy. Br J Haematol 2020;189:1119-26. DOI PubMed
2
93. Nowakowski GS, Willenbacher W, Greil R, et al. Safety and efficacy of PD-L1 inhibitor durvalumab with R-CHOP or R -CHOP in
subjects with previously untreated, high-risk DLBCL. JCO 2019;37:7520-7520. DOI
94. Nowakowski GS, Kalakonda N, Truemper L, et al; And the MEDI4736-DLBCL-001 Trial Investigators. Phase II study of
durvalumab (anti-PD-L1 antibody) in combination with R-CHOP or lenalidomide plus R-CHOP in previously untreated, high-risk
diffuse large B-cell lymphoma. JCO 2017;35:TPS7573-TPS7573. DOI
95. Hawkes EA, Manos K, Smith C, et al. AvR-CHOP: feasibility study of induction and maintenance AVELUMAB plus R-CHOP in
patients with diffuse large B-Cell lymphoma (DLBCL). Blood 2019;134:5332. DOI
96. Klapper W, Stoecklein H, Zeynalova S, et al; German High-Grade Non-Hodgkin's Lymphoma Study Group. Structural aberrations
affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated
within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Leukemia 2008;22:2226-9.
DOI PubMed
97. Valera A, López-Guillermo A, Cardesa-Salzmann T, et al; Grup per l’Estudi dels Limfomes de Catalunya i Balears (GELCAB).
MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with
immunochemotherapy. Haematologica 2013;98:1554-62. DOI PubMed PMC
98. Horn H, Ziepert M, Becher C, et al; German High-Grade Non-Hodgkin Lymphoma Study Group. MYC status in concert with BCL2
and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood 2013;121:2253-63. DOI PubMed
99. Barrans S, Crouch S, Smith A, et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell
lymphoma treated in the era of rituximab. J Clin Oncol 2010;28:3360-5. DOI PubMed
100. Oki Y, Noorani M, Lin P, et al. Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol
2014;166:891-901. DOI PubMed
101. Petrich AM, Gandhi M, Jovanovic B, et al. Impact of induction regimen and stem cell transplantation on outcomes in double-hit
lymphoma: a multicenter retrospective analysis. Blood 2014;124:2354-61. DOI PubMed
102. Wang W, Hu S, Lu X, Young KH, Medeiros LJ. Triple-hit B-cell Lymphoma with MYC, BCL2, and BCL6
translocations/rearrangements: clinicopathologic features of 11 cases. Am J Surg Pathol 2015;39:1132-9. DOI PubMed
103. Hu S, Xu-Monette ZY, Tzankov A, et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell
subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International
DLBCL Rituximab-CHOP Consortium Program. Blood 2013;121:4021-31; quiz 4250. DOI PubMed PMC
104. Morin RD, Johnson NA, Severson TM, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell
lymphomas of germinal-center origin. Nat Genet 2010;42:181-5. DOI PubMed PMC
105. Bödör C, O'Riain C, Wrench D, et al. EZH2 Y641 mutations in follicular lymphoma. Leukemia 2011;25:726-9. DOI PubMed
106. Zhang X, Zhao X, Fiskus W, et al. Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of
histone modification in aggressive B-Cell lymphomas. Cancer Cell 2012;22:506-23. DOI PubMed PMC
107. Yan J, Ng SB, Tay JL, et al. EZH2 overexpression in natural killer/T-cell lymphoma confers growth advantage independently of
histone methyltransferase activity. Blood 2013;121:4512-20. DOI PubMed
108. Arisan S, Buyuktuncer ED, Palavan-Unsal N, Caşkurlu T, Cakir OO, Ergenekon E. Increased expression of EZH2, a polycomb group
protein, in bladder carcinoma. Urol Int 2005;75:252-7. DOI PubMed
109. Velichutina I, Shaknovich R, Geng H, et al. EZH2-mediated epigenetic silencing in germinal center B cells contributes to
proliferation and lymphomagenesis. Blood 2010;116:5247-55. DOI PubMed PMC